P&G stops selling Vicks Action 500 Extra in India after ban

Image
Reuters MUMBAI
Last Updated : Mar 15 2016 | 10:07 AM IST

MUMBAI (Reuters) - U.S. consumer health giant Procter & Gamble's India unit said on Tuesday it had stopped manufacture and sale of its cough-and-cold medicine Vicks Action 500 Extra with immediate effect, after regulators banned it citing potential health risk.

The product is a fixed dose combination of paracetamol, phenylephrine and caffeine, which was banned by India's health ministry in a notice issued over the weekend, Procter & Gamble Hygiene and Health Care Ltd informed the stock exchange.

The drug was one of 344 drug combinations including several antibiotics and analgesics that India ordered to be prohibited saying a government-appointed panel of experts had found the combinations lacked "therapeutic justification."

P&G said all its products, including Vicks Action 500 Extra, were backed by research to support their quality, safety and efficacy.

It wasn't immediately clear how much the product contributed to P&G's sales.

(Reporting by Zeba Siddiqui in Mumbai; Editing by Gopakumar Warrier)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 15 2016 | 9:58 AM IST

Next Story